Related Experiment Video
Updated: Nov 23, 2025
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
Nur Najmi Mohamad Anuar1, Nur Syahidah Nor Hisam1, Sze Ling Liew1
1Programme of Biomedical Science, Centre for Toxicology & Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Abstract:
B-cell lymphoma 2 (BCL-2) family proteins primarily work as a programmed cell death regulator, whereby multiple interactions between them determine cell survival. This explains the two major classes of BCL-2 proteins which are anti-apoptotic and pro-apoptotic proteins. The anti-apoptotic proteins are attractive targets for BCL-2 family inhibitors, which result in the augmentation of the intrinsic apoptotic pathway. BCL-2 family inhibitors have been studied extensively for novel targeted therapies in various cancer types, fibrotic diseases, aging-related as well as autoimmune diseases. Navitoclax is one of them and it has been discovered to have a high affinity toward BCL-2 anti-apoptotic proteins, including BCL-2, BCL-W and B-cell lymphoma-extra-large. Navitoclax has been demonstrated as a single agent or in combination with other drugs to successfully ameliorate tumor progression and fibrosis development. To date, navitoclax has entered phase I and phase II clinical studies. Navitoclax alone potently treats small cell lung cancer and acute lymphocytic leukemia, whilst in combination therapy for solid tumors, it enhances the therapeutic effect of other chemotherapeutic agents. A low platelet count has always associated with single navitoclax treatments, though this effect is tolerable. Moreover, the efficacy of navitoclax is determined by the expression of several BCL-2 family members. Here, we elucidate the complex mechanisms of navitoclax as a pro-apoptotic agent, and review the early and current clinical studies of navitoclax alone as well as with other drugs. Additionally, some suggestions on the development of navitoclax clinical studies are presented in the future prospects section.
Insights
Navitoclax, a BCL-2 inhibitor, targets anti-apoptotic proteins to trigger programmed cell death. Clinical studies show its efficacy in various cancers and fibrotic diseases, with manageable side effects like low platelet count.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- B-cell lymphoma 2 (BCL-2) family proteins regulate programmed cell death, with anti-apoptotic and pro-apoptotic members.
- Inhibitors targeting anti-apoptotic BCL-2 proteins augment the intrinsic apoptotic pathway, offering therapeutic potential.
Purpose of the Study:
- To elucidate the pro-apoptotic mechanisms of Navitoclax.
- To review early and current clinical studies of Navitoclax as a single agent and in combination therapy.
- To present future prospects for Navitoclax clinical development.
Main Methods:
- Review of existing literature on BCL-2 family proteins and Navitoclax.
- Analysis of clinical trial data (Phase I and II) for Navitoclax efficacy and safety.
- Examination of Navitoclax's mechanism of action and drug interactions.
Main Results:
- Navitoclax exhibits high affinity for anti-apoptotic BCL-2 proteins (BCL-2, BCL-W, BCL-XL).
- Navitoclax demonstrates efficacy as a single agent in small cell lung cancer and acute lymphocytic leukemia.
- Combination therapy with Navitoclax enhances chemotherapeutic effects in solid tumors; thrombocytopenia is a known side effect.
Conclusions:
- Navitoclax is a promising BCL-2 inhibitor with broad therapeutic applications in oncology and fibrotic diseases.
- Its efficacy is influenced by BCL-2 family member expression.
- Further clinical development is warranted to optimize its therapeutic use.
